Predict your next investment

HEALTHCARE | Biotechnology
delenex.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$41.3M

About Delenex Therapeutics

Delenex is a biopharmaceutical company focused on the development of locally or topically applied antibody therapeutics. Thereby Delenex aims at extending the benefits of proven antibody therapeutics to a much larger number of patients. Delenex' proprietary PENTRA platform will deliver such novel, potent and safe antibody therapeutics that are well suited for local/topical application.

Delenex Therapeutics Headquarter Location

Wagistrasse 27

Schlieren, CH-8952,

Switzerland

+41-44-730 5180

Latest Delenex Therapeutics News

Cell Medica picks up antibody tech

Jul 7, 2017

Cell Medica picks up antibody tech Latest News Cell Medica picks up antibody tech © Markus Schnatmann / Fotolia 13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody. Cell Medica did not say how much it paid for the Swiss ESBATech spin-off. Delenex Therapeutics AG is a clinical stage biopharmaceutical company focused on the development of locally and systemically applied antibody therapeutics. Delenex’s proprietary Pentrabodies are small, highly potent and stable antibody fragments that have shown they are superior in penetrating tissues and in crossing barriers in the human body. The modular Pentrabody platform has the ability to identify and rapidly generate antibodies of various formats including single chain Fv fragments (scFv), IgG and bispecific antibodies. Cell Medica, which develops, markets and manufactures cellular therapeutics for cancer and viral infections, aims to use the Pentrabody platform to accelerate the development of gene-modified immune cell products with enhanced potency for the treatment of cancer. Delenex technology and expertise will be integrated with Cell Medica’s product development programme aimed at creating next generation Chimeric Antigen Receptor (CAR)-modified cellular immunotherapies with improved functionality and specificity. The deal comes weeks after Cell Medica announced a co-development partnership with Baylor College of Medicine to develop next-generation technologies for engineering immune cells with enhanced functions for the treatment of solid tumours. “We are committed to transforming the treatment of cancer through the significant therapeutic potential of cellular immunotherapy,” commented Gregg Sando, CEO of Cell Medica. “The acquisition of Delenex provides a key enabling technology for the development of an exciting pipeline of next generation CAR-modified cell therapies. We are delighted to welcome the talented team from Delenex and to join the vibrant Swiss biotech community based in Schlieren.” © european-biotechnology-news.com/um

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Delenex Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Delenex Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Delenex Therapeutics Patents

Delenex Therapeutics has filed 7 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/16/2015

3/13/2018

Clusters of differentiation, Cytokines, Ion channels, Immune system, Immunology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/16/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

3/13/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Clusters of differentiation, Cytokines, Ion channels, Immune system, Immunology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.